| TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show |
TG Therapeutics Inc TGTX on Monday reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the consensus of 17 cents. |
benzinga.com |
2025-05-05 20:37:15 |
Czytaj oryginał (ang.) |
| Why TG Therapeutics Stock Was Tumbling Today |
A near-doubling of revenue and a flip into profitability on the bottom line apparently weren't good enough for TG Therapeutics (TGTX -12.32%) shareholders on Monday. |
fool.com |
2025-05-05 19:37:44 |
Czytaj oryginał (ang.) |
| TG Therapeutics: Share Price Slip On Q1 Earnings Unsurprising Given Challenges |
TG Therapeutics' Q1 2025 earnings report showed strong revenue growth, with Briumvi net revenues rising to $119.7m, prompting an increase in full-year revenue guidance. Despite a >15% drop in stock value post-earnings, TGTX shares remain up significantly over 6 months, 1 year, and 5 years, reflecting strong market performance. Briumvi competes well against major MS therapies, boasting superior efficacy, less frequent dosing, and a promising subcutaneous version in development. |
seekingalpha.com |
2025-05-05 17:30:22 |
Czytaj oryginał (ang.) |
| TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript |
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Jenna Bosco - Chief Communications Officer Michael Weiss - Chairman and Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Michael DiFiore - Evercore ISI Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Prakhar Agrawal - Cantor Fitzgerald Operator Greetings, and welcome to TG Therapeutics First Quarter Conference Call and Webcast. |
seekingalpha.com |
2025-05-05 14:55:49 |
Czytaj oryginał (ang.) |
| TG Therapeutics (TGTX) Lags Q1 Earnings Estimates |
TG Therapeutics (TGTX) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to loss of $0.07 per share a year ago. |
zacks.com |
2025-05-05 13:11:06 |
Czytaj oryginał (ang.) |
| TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance |
First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 million Conference call to be held today, Monday, May 5, 2025, at 8:30 AM ET NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent company developments and provided an update on 2025 revenue guidance. Michael S. |
globenewswire.com |
2025-05-05 11:00:00 |
Czytaj oryginał (ang.) |
| TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth |
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-30 15:05:55 |
Czytaj oryginał (ang.) |
| TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update |
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. |
globenewswire.com |
2025-04-30 11:30:00 |
Czytaj oryginał (ang.) |
| TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why |
Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line. |
zacks.com |
2025-04-10 16:51:04 |
Czytaj oryginał (ang.) |
| TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting |
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting. Links to each presentation are included below. |
globenewswire.com |
2025-04-10 11:30:00 |
Czytaj oryginał (ang.) |
| TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting |
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting. Links to each presentation are included below. |
globenewswire.com |
2025-04-08 11:30:00 |
Czytaj oryginał (ang.) |
| TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals |
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis (MS) and the other detailing the experience of seven individuals with MS who switched to BRIUMVI® (ublituximab-xiiy) from a different anti-CD20 monoclonal antibody therapy due to efficacy or tolerability concerns. Details of the publications are provided below. |
globenewswire.com |
2025-04-07 11:30:00 |
Czytaj oryginał (ang.) |
| These Insurance Stocks And Biotech Leader Hit New Highs As Stock Market Crumbles |
Insurance stock Root soared to a new high on Friday. The IBD 50 holding has an ideal Composite and Relative Strength Rating. |
investors.com |
2025-03-21 17:22:45 |
Czytaj oryginał (ang.) |
| Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher |
Trading is subdued with TG Therapeutics, Inc. TGTX on Friday. But the shares remain in an uptrend and there is a good chance the trend will continue. |
benzinga.com |
2025-03-21 13:50:25 |
Czytaj oryginał (ang.) |
| Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? |
TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. |
zacks.com |
2025-03-17 08:35:25 |
Czytaj oryginał (ang.) |
| Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel |
Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and has secured strategic partnerships for azer-cel's development in cancer and autoimmune disorders. TG Therapeutics' BRIUMVI achieved significant sales growth in 2024, supporting positive cash flow and funding for future developments, including azer-cel for autoimmune disorders. DTIL is rated a speculative "Buy" due to its undervaluation, promising pipeline, and strategic partnerships, while TGTX is rated "Hold" due to its full valuation. |
seekingalpha.com |
2025-03-15 10:42:25 |
Czytaj oryginał (ang.) |
| TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials |
TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025, with promising patient enrollment trends. Upcoming pivotal trials and potential label updates for Briumvi, including subcutaneous administration, could enhance patient convenience and treatment efficacy. |
seekingalpha.com |
2025-03-14 16:04:04 |
Czytaj oryginał (ang.) |
| TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter |
TGTX's Briumvi, despite initial struggles, has shown strong performance by consistently beating earnings estimates, even with competition from Roche's Zunovo. Briumvi's competitive advantages include a shorter infusion time, lower malignancy risks, and a more favorable price compared to Ocrevus. TGTX's financial health is solid, with a market cap of $5.7bn and a strong cash position, ensuring an indefinite cash runway. |
seekingalpha.com |
2025-03-12 18:11:27 |
Czytaj oryginał (ang.) |
| S&P 500 Pair, Warren Buffet Pick Lead Five Stocks Near Buy Points Amid Market Shakeout |
These watch list stocks have beenholding near buy points while the market has been breaking down. The post S&P 500 Pair, Warren Buffet Pick Lead Five Stocks Near Buy Points Amid Market Shakeout appeared first on Investor's Business Daily. |
investors.com |
2025-03-08 14:05:07 |
Czytaj oryginał (ang.) |
| Why TG Therapeutics Stock Was Soaring This Week |
Following news of an estimates-topping fourth quarter, TG Therapeutics (TGTX 9.24%) stock was a hot item with investors over the past few days. According to data compiled by S&P Global Market Intelligence, as of mid-afternoon Friday, the biotech's share price had risen by almost 27% week to date. |
fool.com |
2025-03-07 19:23:00 |
Czytaj oryginał (ang.) |
| TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum |
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach, Florida. Links to each presentation are included below. |
globenewswire.com |
2025-02-27 09:30:00 |
Czytaj oryginał (ang.) |
| TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update |
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, March 3, 2025, at 8:30 AM ET to discuss results for the fourth quarter and full year 2024 and to provide a business outlook for 2025. Michael S. |
globenewswire.com |
2025-02-26 09:30:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy |
TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-01-27 15:00:34 |
Czytaj oryginał (ang.) |
| TG Therapeutics: Entering 2025 With Increased Investor Expectations |
TG Therapeutics presented at the JP Morgan Healthcare conference this month and CEO Weiss provided commercial and pipeline updates. Briumvi's strong Q4 2024 performance, with $103.6 million in net sales, and 2025 outlook highlight its growth potential despite recent new competition from Roche's Ocrevus Zunovo. Pipeline updates include subcutaneous Briumvi entering phase 3 trials in mid-2025 and new trials to improve IV Briumvi's convenience, alongside expansion into myasthenia gravis. |
seekingalpha.com |
2025-01-23 16:48:06 |
Czytaj oryginał (ang.) |
| TG Therapeutics: 2025 Revenues Will Smash Expectations |
TG Therapeutics exceeded 2024 revenue guidance by 24%, signaling strong growth and market share capture with its Multiple Sclerosis treatment, Briumvi. 2025 revenue guidance of $540 million implies slower growth, but management and data suggest potential for significantly higher revenue, possibly reaching $605 million. CEO comments and Q4 performance indicate sustained 15-20% new patient growth, bolstered by upcoming advertisements and increased visibility among key opinion leaders. |
seekingalpha.com |
2025-01-21 04:17:41 |
Czytaj oryginał (ang.) |
| TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise |
TG Therapeutics reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides revenue guidance for 2025 and other pipeline goals. |
zacks.com |
2025-01-15 12:10:22 |
Czytaj oryginał (ang.) |
| TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last? |
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-01-15 11:15:33 |
Czytaj oryginał (ang.) |
| TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst |
TG Therapeutics is already marketing an IV infusion of Briumvi, but is also developing a subcutaneous form, which could help it compete with other multiple sclerosis drugs. The company expects to report initial data on the subcutaneous form of Briumvi in early 2025, which could be positive given the company's upbeat statements on its prospects. While the company has approved a $100M share buyback, it only bought back $2.1M in Q3'24. Further buybacks could limit downside in the stock. |
seekingalpha.com |
2025-01-14 01:38:26 |
Czytaj oryginał (ang.) |
| TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 43rd Annual J.P. |
globenewswire.com |
2025-01-09 09:30:00 |
Czytaj oryginał (ang.) |
| Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks. |
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth. |
investors.com |
2024-12-03 18:20:34 |
Czytaj oryginał (ang.) |
| TG Therapeutics to Participate in the Evercore HealthCONx Conference |
Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET |
globenewswire.com |
2024-11-29 10:00:00 |
Czytaj oryginał (ang.) |
| TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ |
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. |
globenewswire.com |
2024-11-21 08:00:00 |
Czytaj oryginał (ang.) |
| Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks. |
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth. |
investors.com |
2024-11-05 16:47:34 |
Czytaj oryginał (ang.) |
| TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates |
TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. The results were slightly underwhelming but generally in line with management expectations of a softer Q3. Now we wait for the important updates in early 2025 — preliminary Q4 net sales of Briumvi, the guidance for 2025, and the preliminary results from subcutaneous Briumvi's trial. |
seekingalpha.com |
2024-11-05 15:50:26 |
Czytaj oryginał (ang.) |
| TG Therapeutics Posts Strong Q3 Briumvi Revenue, Here's Why Shares Fell |
TG Therapeutics' Q3 earnings missed EPS expectations, primarily due to higher non-cash compensation and increased R&D investments, despite Briumvi's revenue growth. Briumvi, a CD20-directed monoclonal antibody for multiple sclerosis, generated $83.3 million in Q3, showing a 15% QoQ growth but a deceleration in revenue growth. The Company raised its full-year revenue guidance to $300-305 million, indicating confidence in Briumvi's market performance despite competitive pressures from Ocrevus and Kesimpta. |
seekingalpha.com |
2024-11-04 22:27:05 |
Czytaj oryginał (ang.) |
| TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript |
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Ed White - H.C. Wainwright Michael DiFiore - Evercore ISI Eric Joseph - JP Morgan Tara Bancroft - TD Cowen Matt Kaplan - Ladenburg Thalmann Mayank Mamtani - B. |
seekingalpha.com |
2024-11-04 13:16:34 |
Czytaj oryginał (ang.) |
| TG Therapeutics (TGTX) Lags Q3 Earnings Estimates |
TG Therapeutics (TGTX) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.73 per share a year ago. |
zacks.com |
2024-11-04 11:10:22 |
Czytaj oryginał (ang.) |
| FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement with TG Therapeutics |
Holly Springs, North Carolina site to provide security of supply for B-cell therapy for relapsing multiple sclerosis Holly Springs, North Carolina site to provide security of supply for B-cell therapy for relapsing multiple sclerosis |
globenewswire.com |
2024-11-04 11:00:00 |
Czytaj oryginał (ang.) |
| AI Stocks Meta, Oracle Lead Five Names Near Buy Points |
Two of the five top stocks to watch this week target the artificial intelligence market. The post AI Stocks Meta, Oracle Lead Five Names Near Buy Points appeared first on Investor's Business Daily. |
investors.com |
2024-11-02 10:00:37 |
Czytaj oryginał (ang.) |
| TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update |
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for the third quarter of 2024 and provide a business outlook for the remainder of the year. Michael S. |
globenewswire.com |
2024-11-01 10:06:00 |
Czytaj oryginał (ang.) |
| Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks. |
None of our picks is Nvidia or Apple or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth. |
investors.com |
2024-10-11 12:00:34 |
Czytaj oryginał (ang.) |
| TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval |
Shares of TG Therapeutics made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS and despite Roche receiving FDA approval for Ocrevus Zunovo. Ocrevus Zunovo's convenience profile does not look threatening and Roche believes it represents an incremental growth opportunity, primarily in treatment centers where IV infusions are not possible. Convenience should also be the third consideration for patients, after efficacy and safety, and Briumvi's position on both still looks strong. |
seekingalpha.com |
2024-09-22 12:17:02 |
Czytaj oryginał (ang.) |
| New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis |
Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate patients switching from prior anti-CD20 treatment can successfully eliminate initial BRIUMVI infusion NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. |
globenewswire.com |
2024-09-18 11:15:00 |
Czytaj oryginał (ang.) |
| New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment |
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment |
globenewswire.com |
2024-09-18 11:00:00 |
Czytaj oryginał (ang.) |
| These 12 Stocks are Ripe for a Short Squeeze |
Subscribers to Chart of the Week received this commentary on Sunday, September 8. |
schaeffersresearch.com |
2024-09-10 14:51:03 |
Czytaj oryginał (ang.) |
| Four Biotech Stocks Rally Toward Buy Points As Funds Load Up |
Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database. |
investors.com |
2024-09-06 17:31:26 |
Czytaj oryginał (ang.) |
| TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting |
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 18 – 20, 2024, in Copenhagen, Denmark. Abstracts are now available online and can be accessed on the ECTRIMS meeting website or at the following link: ECTRIMS 2024 Programme. Details of the presentations are outlined below. |
globenewswire.com |
2024-09-05 11:30:00 |
Czytaj oryginał (ang.) |
| TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback |
TG Therapeutics exceeded Q2 Street consensus estimates, with Briumvi net sales of $72.6 million and total revenues of $73.5 million. Positive cash flow achieved one quarter ahead of my expectations, and full-year guidance range raised by $15 million at the mid-point of the range. TG secured a new $250 million credit facility to retire the old one, and it will use $100 million to buy back shares. |
seekingalpha.com |
2024-08-07 08:59:17 |
Czytaj oryginał (ang.) |
| 2 Biotech Stocks Making Moves Today |
Last month, we took a look at three biotech stocks following a historically bullish month for biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI). |
schaeffersresearch.com |
2024-08-06 19:06:15 |
Czytaj oryginał (ang.) |